Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes

/PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat...

Related Keywords

China ,Hangzhou ,Zhejiang ,Martijn Fenaux ,Nonclinical Development Translational Science At Sciwind ,Prnewswire Sciwind Biosciences Co Ltd ,Nonclinical Development ,Translational Science ,Hangzhou Sciwind Biosciences Co ,Td ,